The Vanderbilt Memory and Alzheimer’s Center is recruiting individuals age 50 and older to participate in a study researching early drivers of Alzheimer’s disease.
A Phase 3 study of an investigational HIV vaccine regimen has been discontinued following a planned, interim review by the study’s independent Data and Safety Monitoring Board. The investigational vaccine was generally safe and well tolerated; however, it was not effective at preventing the acquisition of HIV-1. The results of the uniquely designed and implemented Mosaico study underscore the challenges that have faced the global scientific community in the 40-year search for an HIV vaccine, and may provide important data in the ongoing fight against HIV.
Dr. Ryan Kaple joins structural heart colleagues Dr. Tilak Pasala and Dr. Lucy Safi to offer advanced clinical trials and surgical systems that enhance patient outcomes
The University of Kentucky is a site for the groundbreaking AHEAD study, the first-ever clinical trial to test the effect of lecanemab (investigational antibody) in people who have no cognitive symptoms of Alzheimer’s disease (AD), but in whom biomarker tests indicate amyloid is present in the brain, known as “preclinical” AD.
Chronic venous insufficiency (CVI) is a vascular condition affecting millions of people in the United States in which veins in the leg cannot efficiently carry blood back to the heart for oxygenation. For patients suffering from the condition, malfunctioning valves can cause blood to flow backwards and pool in the veins in the legs, which can lead to significant downstream affects for some people.
Researchers from the Desai Sethi Urology Institute, part of the University of Miami Miller School of Medicine, have launched a study to determine if wearing virtual reality headsets during in-office vasectomy helps relieve patients of procedure-related pain and anxiety.
Resolve Therapeutics, pioneering first-in-class, targeted, safe therapies for underserved autoimmune diseases, today announced that its phase 2 clinical trial of RSLV-132 in patients with long covid has been fully enrolled (NCT04944121).
UC San Diego will be one of multiple sites assessing the safety and efficacy of tecovirimat as a potential treatment for human monkeypox. Marketed as TPOXX, tecovirimat is an antiviral currently approved for treatment of human smallpox in adults and children caused by the variola virus.
The GW School of Medicine and Health Sciences is recruiting participants for the final stage of a clinical trial to evaluate two Omicron-specific vaccines. The study, known as the COVID-19 Variant Immunologic Landscape (COVAIL) trial, is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The George Washington University School of Medicine and Health Sciences has received funding support as an agreement under NIH contract number 75N91019D00024 to Leidos Biomedical Research in Frederick, Maryland.
University of Maryland School of Medicine (UMSOM) researchers opened recruitment this month to assess whether a novel remote therapeutic monitoring system can help people with inflammatory bowel disease (IBD) adhere to their medication regimen, and ultimately improve their symptoms and prevent dangerous flare-ups.
UC San Diego scientists are leading a national early-stage clinical trial to assess the safety and efficacy of using bacteriophages to treat drug-resistant bacterial infections in cystic fibrosis patients.
Three babies have been born after receiving the world’s first spina bifida treatment combining surgery with stem cells. This was made possible by a landmark clinical trial at UC Davis Health known formally as the “CuRe Trial: Cellular Therapy for In Utero Repair of Myelomeningocele.”
The National Institutes of Health's National Institute on Aging (NIA) recently awarded researchers from Indiana University's School of Public Health-Bloomington and School of Medicine $3.96 million to fund a five-year, randomized clinical trial of an Alzheimer’s disease and related dementia (ADRD) telehealth intervention.
The UCLA Clinical AIDS Research and Education (CARE) Center today announced its participation in STOMP (Study of Tecovirimat for Human Monkeypox Virus), or A5418, a phase 3, randomized, placebo-controlled, double-blind trial evaluating the safety and efficacy of tecovirimat for the treatment of human monkeypox. STOMP, which is being led by the AIDS Clinical Trials Group (ACTG), has been designed to learn as much as possible in a broad population of people with monkeypox.
With the support of a five-year, $3.5 million grant from the National Institutes of Health (NIH), researchers will study how the COVID-19 pandemic impacted opioid use disorder and how the COVID-19 response and mitigation policies impact health outcomes, especially in vulnerable populations.
Ismael Seáñez will lead an interdisciplinary team of Washington University researchers and physicians to understand the changes in the neural circuits that may result in motor function improvements through using spinal cord stimulation.
A clinical trial investigating the effects of different treatments, including light exercise and screen time restrictions, on recovery from a sport-related concussion among adolescents has opened for enrollment at UTHealth Houston.
UC Davis Health is recruiting people for a clinical trial, BrainGate2, with the goal of building a “neurological prosthesis” for restoring speech to people who have lost — or are losing — the ability to speak due to injuries like stroke or diseases like ALS.
With the support of Harrington Discovery Institute at University Hospitals (UH), an ophthalmic therapeutic dubbed KIO-301, which was initially developed by Richard Kramer, PhD, at the University of California, Berkeley (UCB), has successfully been granted approval to start a Phase 1b, first-in-human clinical trial. Currently under the stewardship of Kiora Pharmaceuticals, Inc., (NASDAQ: KPRX) via a license with UCB, Inc., the drug is intended to restore lost vision in patients with Retinitis Pigmentosa (RP)--a rare, genetic eye disease that causes severe loss of functional vision and affects an estimated 100,000 people in the U.S.
The Phase I clinical trial will test umbilical cord-derived stem cells to treat two rare autoimmune conditions.
The Patient-Centered Outcomes Research Institute (PCORI) has awarded a Georgetown University Medical Center research team led by Dan Merenstein, MD, professor of family medicine at Georgetown’s School of Medicine, $23.6 million in research funding to study treatments for acute rhinosinusitis.
MedStar Washington Hospital Center successfully implanted the first dual-chamber leadless pacemaker system in the Baltimore-Washington region this week. Known as the Aveir™ DR Leadless Pacemaker System, this breakthrough technology is being clinically evaluated as part of a worldwide clinical trial sponsored by Abbott, and MedStar Washington Hospital Center was the only hospital in the region selected to participate.
MD Anderson and Obsidian Therapeutics announce FDA clearance of an Investigational New Drug Application for the novel TIL therapy OBX-115, developed under a strategic collaboration. The first-in-human Phase I study will be led at MD Anderson.
With a $45 million grant from the NIH, UC San Diego researchers and collaborators will launch a nationwide clinical trial to further investigate the therapeutic potential of benfotiamine, a synthetic version of thiamine (B1), as a treatment for Alzheimer’s disease.
Under a Defense Advanced Research Projects Agency (DARPA) and Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) funded program, a novel COVID-19 antibody delivery approach has advanced to clinical trials.
Researchers at Wake Forest University School of Medicine receive $3.1 million grant to lead a multi-site study to look for the earliest signs of heart vessel damage in young, pre-menopausal breast cancer survivors.
Joseph M. Sanzari Children’s Hospital at Hackensack University Medical Center — a member of the global Pacific Pediatric Neuro-Oncology Consortium (PNOC) research group — is participating in a PNOC clinical trial for children and young adults with recurrent or progressive high-grade glioma (HGG), an aggressive, fast-growing type of brain tumor. The hospital is one of only 12 centers in the U.S., and the only center in the New York metropolitan area, to offer this trial.
An important new study of diverse communities is looking at how brain changes, genetics and other factors contribute to dementia and Alzheimer’s disease. The results could affect millions. Among people 65 and older, about 1 in 9 has Alzheimer’s disease.
The immunotherapy SurVaxM is being utilized in a pilot study in children and adolescents with several brain cancer types through a multicenter trial sponsored by the Pediatric Brain Tumor Consortium (PBTC).
Emergency Medicine and Trauma Surgery researchers at Vanderbilt University Medical Center (VUMC) are joining Vanderbilt LifeFlight in a Department of Defense (DOD)-funded clinical trial aimed at improving survival with resuscitation techniques used to keep patients alive after a traumatic injury.
Researchers at Saint Louis University School of Medicine are enrolling volunteers in an investigational drug trial for hypogonadal men with chronic kidney disease.
Susan G. Komen awarded a research grant to apply a new, first-of-its-kind tool that seeks to more accurately diagnose inflammatory breast cancer (IBC).
Curtin University researchers will examine if the long-term use of a popular blood pressure medication increased the risk of breast cancer in almost 200,000 women as part of a new project supported by the Federal Government.
SEATTLE (May 18, 2022) – Building on momentum from the highly successful COVID-19 vaccine clinical trials, the HIV Vaccine Trials Network (HVTN) is launching a new HIV awareness campaign and unveiling a first-of-its-kind national registry that will provide updated HIV information and make it easier to learn about and participate in HIV clinical trials at HelpEndHIV.org.
In early research led by the University of Michigan Health Rogel Cancer Center, the oral medication zanubrutinib was found to help most patients with a slow-growing type of cancer known as marginal zone lymphoma.
A phase 2 clinical trial testing novel immunotherapy combinations in aggressive ovarian cancer has opened and first patients have begun treatment.
A stroke and subsequent brain injury qualified 65-year-old Linda Carmichael for a national, randomized clinical trial led locally by Sunil A. Sheth, MD, with McGovern Medical School at UTHealth Houston, investigating the safety and efficacy of endovascular thrombectomy plus medical management compared to medical management alone in certain LVO stroke patients.
With the support of a $1.7 million grant from the National Institutes of Health, researchers at the School of Medicine will lead the Long-term Effectiveness of the Anti-Obesity medication Phentermine (LEAP) trial, a placebo-controlled, randomized-controlled trial that will enroll 1,000 adults at five sites across the U.S.
In a research letter to the journal JAMA Oncology, clinical researchers at Sylvester Comprehensive Cancer Center in the University of Miami Miller School of Medicine showed that immunotherapy can be an option for at least one subgroup of pancreatic cancer patients. The study found that patients with inherited BRCA and other similar mutations can achieve complete responses — in some cases going from near death to durable recoveries.
Bladder cancer affects nearly 84,000 people in the United States each year, making it the sixth most common cancer. Most people survive it, but unfortunately, many lose their bladders. Neda Hashemi, MD, and her team at The University of New Mexico Comprehensive Cancer Center are now offering several clinical trials, including one that will give people with bladder cancer a chance to fight their disease and keep their bladders.
Researchers at Wake Forest University School of Medicine have been awarded a five-year, $4 million grant through the National Institutes of Health (NIH) Helping End Addiction Long-term (HEAL) Initiative to study chronic pain and opioid use disorder.
A team of clinical investigators at the Icahn School of Medicine at Mount Sinai has announced the launch of a Phase 1, open-label, placebo-controlled study to evaluate the safety and immunogenicity of an egg-based COVID-19 vaccine in healthy, vaccinated adults who have never been infected with COVID-19.
Now a couple of years after this discovery, Pete Nelson, the R.C. Durr Foundation Chair in Alzheimer's Disease at the University of Kentucky, is working towards the second part of the dream, with the world’s first clinical trial for LATE officially underway by his colleagues at UK.
The Dementia Care Study (D-CARE), a nation-wide clinical trial assessing the effectiveness of different approaches to caring for people with Alzheimer’s disease and other dementias, has reached its recruitment goal by enrolling 2,176 persons living with dementia and their caregivers
University of Utah Health researchers are leading a five-year, $22-million nationwide clinical trial for NMDA receptor encephalitis––a type of autoimmune encephalitis that prompts the immune system to mistakenly attack the brain, causing confusion, memory loss, seizures, and symptoms similar to bipolar disorder and other psychiatric conditions.
African Americans have an increased risk of kidney failure, and new research shows that some of this risk is related to variations in a gene called apolipoprotein L1 (APOL1). Scientists will address racial disparities in kidney transplant outcomes.
Experts at Overlook are hoping that SurVaxM, a first-of-its-kind vaccine targeting a protein found in glioblastomas and other cancers, will give patients a better shot at long-term survival and improved function.
The UNM Comprehensive Cancer Center has opened the Targeted Agent and Profiling Utilization Registry (TAPURTM) Study, sponsored by the American Society of Clinical Oncology (ASCO). The clinical trial is cancer agnostic. It may help people who have rare cancer mutations and enable them to receive personalized cancer therapy.
A trial investigating a potential electric biomarker for mild traumatic brain injury is now recruiting teenage and adult patients at The University of Texas Health Science Center at Houston (UTHealth Houston).
Roswell Park Comprehensive Cancer Center is the first center to treat patients in a newly opened advanced-stage clinical trial utilizing the brain cancer vaccine SurVaxM, offering a new treatment option for patients who are dealing with a rare but deadly form of the disease. The multicenter randomized clinical trial is sponsored by MimiVax LLC, a company spun off from Roswell Park in 2012.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
